Table 2.

Effects of PCO induction by testosterone enanthate and resveratrol on body composition

Groups	Control (n= 5)	PCO-model-saline (n= 5)	PCO-model-resveratrol (n= 5)
Body weight at the beginning of treatment with testosterone enanthate (g) (At 21 days of age)	24.40±1.631	25.80±2.518	27.00±1.581
Initial body weight at the beginning of treatment with resveratrol or saline (g) (At 56 days of age)	166.8±5.543	201.6±7.174**	207.0±3.647***
Final body weight at the end of treatment with resveratrol or saline (g) (At 84 days of age)	204.8± 5.044	205.8± 9.124	224.2± 5.380Ψ
Weights of parametrial fat depots (g)(At 84 days of age)	3.434±0.1192	5.710±0.07085***	5.196± 0.1143***, Ψ
Partial weights of parametrial fat depots (%) (g) (At 84 days of age)	1.684±0.09373	2.810±0.08620***	2.319±0.02848***, ΨΨ
Weights of retroperitoneal fat depots (g) (At 84 days age)	2.134±0.07646	3.180±0.08854***	3.130±0.1242***
Partial weights of retroperitoneal fat depots (%) (At 84 days age)	1.040±0.02168	1.553±0.06112***	1.398±0.05152***

The data are expressed as mean±SEM. The data analysis was done using one-way ANOVA followed by the Tukey’s Post hoc test. P-values less than 0.05 were considered statistically significant. The abbreviations represent the following: Control: Normal control rats; PCO-Model-Saline: these rats received testosterone enanthate 1 mg/100 g body weight subcutaneously for 35 days once daily. Then, saline was injected into them intraperitoneally for 4 weeks once daily; PCO-Model resveratrol: these rats received testosterone enanthate 1 mg/100 g body weight subcutaneously for 35 days once daily. Then, resveratrol 10 mg/kg was injected into them intraperitoneally for 28 days once daily.

^**: P<0.01 vs. Control;

^***: P<0.001 vs. Control;

^Ψ: P<0.05 vs. PCO-model-saline;

^ΨΨ: P<0.05 vs. PCO-model-saline